The role of 111In Capromab Pendetide (ProstaScintR) immunoscintigraphy in the management of prostate cancer

L. M. Freeman, B. R. Krynyckyi, Y. Li, G. Korupulu, K. Saleemi, M. K. Haseman, D. Kahn

Research output: Contribution to journalArticle

28 Scopus citations

Abstract

111In Capromab Pendetide (ProstaScintR) is a whole murine antibody that is reactive with prostate specific membrane antigen (PSMA), a glycoprotein on the surface of normal and abnormal prostate epithelium. It has proven to be of great value in assisting management decisions in prostate cancer patients who initially present with high risk for metastatic spread, or who develop a picture of recurrent disease after surgery or radiation therapy. Patterns of metastatic lymphatic spread have correlated well with autopsy reports in the literature. Unfortunately, other imaging study and/or histologic confirmation of scintigraphic findings has been difficult to obtain. Prostascint's role in predicting durable complete response (DCR) in postoperative patients having salvage radiotherapy to their prostate fossa is very promising. Further investigative work in larger patient populations is needed to confirm these early results.

Original languageEnglish (US)
Pages (from-to)131-137
Number of pages7
JournalQuarterly Journal of Nuclear Medicine
Volume46
Issue number2
StatePublished - Jun 1 2002

Keywords

  • Antibodies, monoclonal
  • Lymph nodes, radionuclide imaging
  • Prostatic neoplasms, diagnosis
  • Prostatic neoplasms, radionuclide imaging

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'The role of <sup>111</sup>In Capromab Pendetide (ProstaScint<sup>R</sup>) immunoscintigraphy in the management of prostate cancer'. Together they form a unique fingerprint.

  • Cite this

    Freeman, L. M., Krynyckyi, B. R., Li, Y., Korupulu, G., Saleemi, K., Haseman, M. K., & Kahn, D. (2002). The role of 111In Capromab Pendetide (ProstaScintR) immunoscintigraphy in the management of prostate cancer. Quarterly Journal of Nuclear Medicine, 46(2), 131-137.